Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза IV Россия

Insulin glargine; Insulin Detemir

Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.

Номер протоколаLANTU_C_00579
ФазаФаза IV
Участников по плану — во всех странах исследования973
Сроки01.11.2006 — …

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00405418/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 40–75 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 973 чел. во всех странах исследования.
  • Центров в реестре: 1 в одном городе. Список — ниже на странице.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст40–75 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 15

Критерии включения

  • Type 2 diabetes for at least 1 year
  • Insulin naïve
  • Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
  • 7% ≤ HbA1c ≤ 10.5 %
  • Body mass index (BMI) < 40 kg/m²
  • Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary

Критерии невключения

  • Type 1 diabetes
  • Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
  • Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors
  • Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
  • Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
  • Breast-feeding
  • History of hypersensitivity to the study drugs or to drugs with a similar chemical structure
  • Treatment with systemic corticosteroids in the 3 months prior to study entry
  • Treatment with any investigational product in the 2 months prior to study entry
  • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
  • Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
  • Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry
  • Impaired renal function as shown by serum creatinine ≥ 1.5 mg/dL (≥ 133 μmol/L) in men and ≥ 1.4 mg/dL (124 μmol/L) in women at study entry
  • History of drug or alcohol abuse in the last year
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Источник: ClinicalTrials.gov, NCT00405418 · запись обновлена в реестре 15 сентября 2009.

Дизайн и результаты

ДизайнРандомизированное, открытое (без ослепления), параллельные группы; цель — лечение
Включено участников (факт, все страны)973
Результатыв реестре не опубликованы
Что измеряют — первичные конечные точки (5), вторичных — 9
  • HbA1c recorded — At baseline, week 12 and week 24
  • Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir arm — On the 4 consecutive days before each visit
  • Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive days — Within the week prior to baseline, week 12 and week 24
  • Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic) — All across the study
  • Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia. — All across the study

Цель исследования

Primary objective:

To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c \< 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L)

Secondary objectives:

* To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c \< 7% and \< 6.5% at the end of the treatment period
* To compare the changes in HbA1c and fasting plasma glucose (FPG)
* To compare the evolution of blood glucose profiles
* To compare the day to day FPG variability, the insulin doses
* To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets
* To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L)
* To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL \[3.9 mmol/L\]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL
* To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio
* To assess the quality of life and treatment satisfaction

Где проходит

1 центр в 1 городе
Москва

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00405418 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.